---
document_datetime: 2023-09-21 17:11:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/refludan-epar-all-authorised-presentations_en.pdf
document_name: refludan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9556172
conversion_datetime: 2025-12-22 12:04:53.429832
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical Form                    | Route of Administration   | Packaging    | Content         | Package size   |
|-----------------|-----------------|------------|----------------------------------------|---------------------------|--------------|-----------------|----------------|
| EU/1/97/035/001 | Refludan        | 50 mg      | Concentrate for solution for injection | Intravenous use           | vial (glass) | 1 ml            | 1 vial         |
| EU/1/97/035/002 | Refludan        | 50 mg      | Concentrate for solution for injection | Intravenous use           | vial (glass) | 1 ml authorised | 10 vials       |
| EU/1/97/035/003 | Refludan        | 20 mg      | Concentrate for solution for injection | Intravenous use           | vial (glass) | 0.4 ml          | 1 vial         |
| EU/1/97/035/004 | Refludan        | 20 mg      | Concentrate for solution for injection | Intravenous use           | vial (glass) | 0.4 ml          | 10 vials       |

Medicinal product no longer authorised